We show that T cells from XLP patients corrected by gene editing tools have restored physiological levels of SAP gene expression and restore SAP-dependent immune functions, indicating a new therapeutic opportunity for XLP patients. The gene discussed is SH2D1A; the disease is X-linked lymphoproliferative disease.